About this session
Blood is a remarkable tissue that sustains human life. However, when mutations arise in stem cells in the bone marrow, acute myeloid leukaemia can develop. This is an extremely aggressive blood cancer that increases with age and carries a poor prognosis. Despite extensive research, treatment options are often limited with most patients unsuitable for stem cell transplantation.
Recent advances have brought hope of novel drugs targeted at key genetic mutations. Some of these involve epigenetic genes that regulate the cell through a process called DNA methylation. Understanding how this causes leukaemia has been the major focus of a bench-to-bedside research programme at BSMS for over 15 years that aims to bring new treatments to patients.
Profess Chevassut will be reflecting on his contribution as a researcher, educator and physician. He will also touch on the Covid-19 pandemic, juggling life in academia and medicine, and how haematology is, quite literally, in his blood.
Book your place here >